Using clinically tested HER2 CAR T cells (16), we demonstrate in this article that HER2-specific CAR T cell treatment of CAM-grown, HER2-expressing solid tumors reduced the presence of viable tumor cells and Ki-67 staining in tumors. Here, MKI67 is linked to neoplasm.